Marker Therapeutics to be Acquired by 03 Life Sciences
Ticker: MRKR · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | mixed |
Sentiment: mixed
Topics: acquisition, merger, biotech
TL;DR
Marker Therapeutics is getting bought by 03 Life Sciences, closing Q4 2025.
AI Summary
Marker Therapeutics, Inc. announced on August 7, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This acquisition aims to combine Marker's expertise in cell therapies with 03 Life Sciences' broader oncology platform.
Why It Matters
This acquisition could lead to significant advancements in cancer treatment by integrating Marker's cell therapy technology with 03 Life Sciences' existing oncology pipeline.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions, and the integration of the two companies may present challenges.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquiring entity
- August 7, 2025 (date) — Date of earliest event reported
- fourth quarter of 2025 (date) — Expected closing period of acquisition
FAQ
What is the exact date of the report?
The date of the report is August 7, 2025.
What is the exact name of the registrant?
The exact name of the registrant is Marker Therapeutics, Inc.
In which state was Marker Therapeutics, Inc. incorporated?
Marker Therapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Marker Therapeutics, Inc.?
The Commission File Number for Marker Therapeutics, Inc. is 001-37939.
When is the acquisition by 03 Life Sciences expected to close?
The acquisition by 03 Life Sciences is expected to close in the fourth quarter of 2025.
Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2025-08-12 16:08:23
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2421372d1_8k.htm (8-K) — 30KB
- tm2421372d1_ex16-1.htm (EX-16.1) — 3KB
- 0001104659-25-076834.txt ( ) — 240KB
- mrkr-20250807.xsd (EX-101.SCH) — 3KB
- mrkr-20250807_def.xml (EX-101.DEF) — 26KB
- mrkr-20250807_lab.xml (EX-101.LAB) — 35KB
- mrkr-20250807_pre.xml (EX-101.PRE) — 24KB
- tm2421372d1_8k_htm.xml (XML) — 5KB
01 Changes in Registrant's Certifying
Item 4.01 Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP ("Marcum"), the former independent registered public accounting firm of Marker Therapeutics, Inc. (the "Company"), CBIZ CPAs P.C. ("CBIZ CPAs") acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company's independent registered public accounting firm through August 6, 2025. On August 6, 2025, Marcum resigned as the Company's independent registered public accounting firm and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective beginning with the review of the Company's condensed consolidated financial statements for the quarter ended June 30, 2025. The engagement of CBIZ CPAs was approved by the Company's Board of Directors. The services previously provided by Marcum will now be provided by CBIZ CPAs. Marcum's report regarding the Company's consolidated financial statements for the years ended December 31, 2024 and 2023 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except that such report contained an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern. During the years ended December 31, 2024 and 2023, and through August 6, 2025, the date of Marcum's resignation, there were (a) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with Marcum's reports on the Company's financial statements, and (b) no "re
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 16.1 Letter from Marcum LLP dated August 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: August 12, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer